“
“Fexofenadine HCl (FEXO), chemically designated as (±)-4-[1-hydroxy-4-(4 hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-∝,∝-dimethyl benzeneacetic acid hydrochloride 1 is a histamine H1 receptor antagonist used in patients with allergic rhinitis. It is freely soluble in methanol, ethanol and slightly soluble in water, chloroform and practically insoluble AZD2281 in hexane. The molecular weight is 538.13 and the empirical formula is C32H39NO4•HCl.1, 2, 3, 4 and 5 Montelukast Sodium (1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl) ethenyl]

phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] -propyl] thio] methyl] cyclopropaneacetic acid, monosodium salt is a white colored powder and it is freely soluble in ethanol, methanol, and water and practically insoluble in acetonitrile. Molecular weight of Montelukast Sodium is 608.2 g/mol and formula is C35H35ClNO3S.Na1, 2, 3, 4 and 5 It has been demonstrated in recent studies that the treatment of allergic rhinitis with concomitant administration of an anti-leukotriene and an antihistamine shows significantly better symptom relief compared with the modest improvement in rhinitis symptomatology with each of the treatments alone. The review of literature revealed that several methods are available for the determination of Montelukast Sodium

and Fexofenadine hydrochloride individually. Reported method for estimation Fexofenadine hydrochloride in dosage form are spectrop-hotometry,6, 7, 8 and 9 spectrofluorometry,10, 11 and 12 dissolution,13 RP-HPLC14, 15, 16, 17, 18 and 19, and similarly for estimation Montelukast Sodium Selleck Crizotinib in dosage form are spectrophotometry,20,

21 and 22 spectrofluorometry,23 LC-MS,24 and 25 RP-HPLC26, 27, 28, 29 and 30 and HPTLC.31, 32 and 33 Figure options Download full-size image Download as PowerPoint slide But, there is no any analytical method has been reported yet for combination of these drugs. There for the present research work aims to develop a simple, sensitive, accurate and reproducible method for simultaneous estimation of Montelukast Sodium and Fexofenadine hydrochloride in combined dosage form by RP-HPLC method. Active pharmaceutical ingredient of Montelukast Sodium and Fexofenadine hydrochloride Sitaxentan was obtained as a gift sample from Calida Pharmaceutical Pvt. Ltd and Ami Life Science Pvt. Ltd, India. The HPLC (Shimadzu) Liquid Chromatograph – LC-2010 CHT with UV–Visible detector: SPD-M20A. Column used was X-bridge C18, 5 μm (250 mm × 4.6 mm). The system was run at a flow rate of 1.0 mL/min, 20 μL of sample was injected in the chromatographic system and a UV–Visible detector was used for simultaneous determination of Montelukast Sodium and Fexofenadine hydrochloride. Mobile phase comprising of 50 mM Sodium acetate buffer:acetonitrile:methanol (25:35:40) adjust pH 8.2 with 5% o-phosphoric acid at a flow rate of 1.0 mL/min. Column temperature was maintained at 40 ± 2 °C and UV detection at 210 nm.